Comparison of the 3 cytogenetic subgroups (S) (MYC translocation, MYC gain, and no MYC activation): significant results
| Parameter . | S1: t(MYC) (n = 21 [62%]) . | S2: MYC gain (n = 5 [15%]) . | S3: no MYC (n = 8 [23%]) . | Comparison . | P . |
|---|---|---|---|---|---|
| Prolymphocytes (range), % | 86 (61-100) | 79 (66-91) | 76 (60-80) | S1 vs S2 + S3 | .03 |
| S3 vs S1 + S2 | .03 | ||||
| CD38+, n/N (%) | 18/20 (90) | 2/5 (40) | 0/8 (0) | S1 vs S2 + S3 | <.0001 |
| S3 vs S1 + S2 | <.001 | ||||
| No. of chromosomal abnormalities (range) | 3 (1-9) | 6 (5-21) | 10 (1-15) | S1 vs S2 + S3 | .0005 |
| S3 vs S1 + S2 | .02 | ||||
| HCK (≥5 abnormalities), n/N (%) | 4/20 (20) | 5/5 (100) | 6/8 (75) | S1 vs S2 + S3 | .0004 |
| S2 vs S1 + S3 | .01 | ||||
| Unbalanced translocations, n/N (%) | 11/20 (55) | 5/5 (100) | 7/8 (88) | S1 vs S2 + S3 | .04 |
| del17p, n/N (%) | 3/21 (14) | 4/5 (80) | 6/8 (75) | S1 vs S2 + S3 | .0006 |
| S3 vs S1 + S2 | .03 | ||||
| tri3, n/N (%) | 4/20 (20) | 4/5 (80) | 0/8 (0) | S2 vs S1 + S3 | .008 |
| Parameter . | S1: t(MYC) (n = 21 [62%]) . | S2: MYC gain (n = 5 [15%]) . | S3: no MYC (n = 8 [23%]) . | Comparison . | P . |
|---|---|---|---|---|---|
| Prolymphocytes (range), % | 86 (61-100) | 79 (66-91) | 76 (60-80) | S1 vs S2 + S3 | .03 |
| S3 vs S1 + S2 | .03 | ||||
| CD38+, n/N (%) | 18/20 (90) | 2/5 (40) | 0/8 (0) | S1 vs S2 + S3 | <.0001 |
| S3 vs S1 + S2 | <.001 | ||||
| No. of chromosomal abnormalities (range) | 3 (1-9) | 6 (5-21) | 10 (1-15) | S1 vs S2 + S3 | .0005 |
| S3 vs S1 + S2 | .02 | ||||
| HCK (≥5 abnormalities), n/N (%) | 4/20 (20) | 5/5 (100) | 6/8 (75) | S1 vs S2 + S3 | .0004 |
| S2 vs S1 + S3 | .01 | ||||
| Unbalanced translocations, n/N (%) | 11/20 (55) | 5/5 (100) | 7/8 (88) | S1 vs S2 + S3 | .04 |
| del17p, n/N (%) | 3/21 (14) | 4/5 (80) | 6/8 (75) | S1 vs S2 + S3 | .0006 |
| S3 vs S1 + S2 | .03 | ||||
| tri3, n/N (%) | 4/20 (20) | 4/5 (80) | 0/8 (0) | S2 vs S1 + S3 | .008 |